List of Excipients in Branded Drug DRONABINOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Major Pharmaceuticals	DRONABINOL	dronabinol	0904-7068	GELATIN
Major Pharmaceuticals	DRONABINOL	dronabinol	0904-7068	GLYCERIN
Major Pharmaceuticals	DRONABINOL	dronabinol	0904-7068	SESAME OIL

Generic Drugs Containing DRONABINOL

Company	Ingredient	NDC	Excipient
Lannett Company Inc	dronabinol	0527-1450	FD&C RED NO. 40
Lannett Company Inc	dronabinol	0527-1450	GELATIN
Lannett Company Inc	dronabinol	0527-1450	GLYCERIN

What are the Most Frequently-Used Excipients in DRONABINOL?

# Of NDCs	Excipient
6	AMMONIA
6	BUTYL ALCOHOL
3	BUTYLATED HYDROXYTOLUENE

Dronabinol Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Dronabinol is a lipophilic, poorly water-soluble cannabinoid with established FDA-approved capsule and oral-solution products. The main excipient opportunities are improved solubilization, reduced food-effect variability, taste masking, alcohol-free delivery, dose flexibility, and differentiated administration formats. The strongest commercial positions are likely to come from formulation performance and patient usability rather than composition-of-matter protection, because dronabinol has been marketed for decades and generic capsule competition exists.

What is the FDA regulatory status of dronabinol?

Dronabinol is synthetic delta-9-tetrahydrocannabinol, or delta-9-THC. FDA-approved products are indicated for:

• Anorexia associated with weight loss in patients with AIDS.
• Nausea and vomiting associated with cancer chemotherapy in patients who have failed conventional antiemetic therapy.

The principal U.S. products are:

Product	Active ingredient	Dosage form	Strength	FDA sponsor	Initial approval
Marinol	Dronabinol	Sesame-oil-filled gelatin capsule	2.5, 5, 10 mg	AbbVie, formerly Unimed	1985
Syndros	Dronabinol	Oral solution	5 mg/mL	Benuvia Therapeutics	2016
Generic dronabinol	Dronabinol	Capsule	Generally 2.5, 5, 10 mg	Multiple ANDA sponsors	Subsequent approvals

Marinol is a Schedule III controlled substance. Syndros is a Schedule II controlled substance because its liquid formulation was classified differently under the Controlled Substances Act. The scheduling distinction affects distribution, prescribing controls, abuse-deterrence considerations, and commercial positioning.

Syndros was approved under NDA 205525. Marinol was approved under NDA 018651. FDA product labels remain the primary sources for approved inactive ingredients, dosing instructions, warnings, and controlled-substance classification.[1][2]

What excipients are used in approved dronabinol products?

Approved products use materially different formulation approaches.

Marinol capsule excipients

Marinol uses an oil-based soft gelatin capsule. Its formulation includes sesame oil as the vehicle, with gelatin, glycerin, and titanium dioxide associated with the capsule shell. The oil vehicle accommodates the lipophilic active ingredient and supports oral absorption.

The capsule approach has several limitations:

• Sensitivity to food intake and dietary fat.
• Potential variability in absorption.
• Limited dose flexibility between marketed strengths.
• Difficulty swallowing for some patients.
• Sesame-related allergen concerns.
• Dependence on softgel manufacturing and capsule-shell performance.

Generic dronabinol capsules generally compete through the same basic dosage-form architecture. This limits differentiation unless a sponsor can demonstrate a meaningful improvement in bioavailability, stability, tolerability, manufacturing cost, or patient administration.

Syndros oral-solution excipients

Syndros uses a solubilized liquid formulation containing excipients such as alcohol, propylene glycol, polyethylene glycol 400, sucralose, and flavoring components. The solution provides a 5 mg/mL concentration and enables measured dosing with an oral syringe or other dosing device.

The oral solution addresses several capsule limitations:

• Dose titration in smaller increments.
• Use by patients who cannot swallow capsules.
• More flexible administration in institutional and caregiver settings.
• Potentially simpler dose adjustment during treatment initiation.
• Better suitability for patients with chemotherapy-related swallowing or gastrointestinal problems.

The formulation also introduces commercial constraints. Ethanol and propylene glycol may create concerns for certain patients, caregivers, hospitals, pediatric-use discussions, and institutional formularies. Taste, odor, dosing accuracy, storage, and controlled-substance handling are important product attributes.

What formulation problems create the largest excipient opportunities?

How can excipients improve dronabinol solubility?

Dronabinol is highly lipophilic and has low aqueous solubility. A formulation must either maintain the drug in a suitable lipid phase or use a solubilization system that prevents precipitation after dilution in gastrointestinal fluids.

Potential excipient platforms include:

• Medium-chain triglycerides.
• Long-chain triglycerides.
• Mixed glycerides.
• Self-emulsifying drug-delivery systems.
• Micellar surfactant systems.
• Cosolvent blends.
• Cyclodextrin complexes.
• Phospholipid-based systems.
• Amorphous solid dispersions.
• Nanodispersions and nanosuspensions.

A successful system must be evaluated beyond initial solubility. Critical performance variables include precipitation after dilution, digestion-mediated release, chemical stability, dose uniformity, gastrointestinal tolerability, and compatibility with packaging.

For dronabinol, self-emulsifying and lipid-based systems are commercially attractive because they address the drug's physicochemical characteristics using familiar oral excipient technologies. The main development risk is that a formulation with high apparent solubility may not produce consistent in vivo exposure.

Can excipients reduce food-effect variability?

Food-effect management is a central development opportunity. Fat-rich meals can alter the absorption of lipophilic drugs by increasing solubilization and stimulating bile secretion. A product that depends heavily on dietary fat can produce inconsistent exposure between fed and fasted conditions.

Excipient strategies may reduce this variability by:

• Incorporating a pre-solubilized lipid phase.
• Using digestion-resistant surfactant systems.
• Controlling droplet size after dilution.
• Adding precipitation inhibitors.
• Using phospholipid or bile-compatible systems.
• Designing a formulation with reproducible dispersion independent of meal composition.

A sponsor would need comparative pharmacokinetic evidence against an approved reference product. A lower fed/fasted exposure ratio alone may not support a commercial claim unless it translates into a clinically useful dosing advantage.

How can taste and mouthfeel be improved?

Dronabinol has a strong cannabinoid-associated taste and odor profile. The current oral solution uses sweetening and flavoring, but taste masking remains relevant for chronic use and repeated dosing.

Possible approaches include:

• Ion-exchange resin complexes.
• Cyclodextrin inclusion complexes.
• Lipid encapsulation.
• Polymer coating.
• Multiparticulate systems.
• Flavor systems designed for bitter and aromatic compounds.
• Metered-dose oral films or dispersible dosage forms.

Taste masking must preserve dose uniformity and release. Strong flavoring can create its own tolerability problems, while resin or polymer systems can delay release or reduce bioavailability.

Which excipients could enable an alcohol-free oral solution?

An alcohol-free dronabinol solution would target patients and institutions that prefer to avoid ethanol. Candidate approaches include:

• Propylene glycol and polyethylene glycol systems.
• Glycerol-based cosolvent systems.
• Solubilizing surfactants.
• Lipid nanoemulsions.
• Cyclodextrin derivatives.
• Water-dispersible prodrug or complexation approaches.

The main technical challenge is maintaining a clear, stable, dose-uniform product at a practical concentration. Removing ethanol may increase precipitation risk, microbial-control requirements, viscosity, and packaging complexity.

An alcohol-free product could have commercial relevance in institutional care, home health, patients with alcohol restrictions, and procurement systems that favor simplified inactive-ingredient profiles.

What formulations are most commercially attractive?

Formulation concept	Primary value proposition	Main technical risk	Commercial potential
Alcohol-free oral solution	Broadens acceptability and institutional use	Precipitation and microbial stability	High
Lipid self-emulsifying solution	Improves solubilization and may reduce food effect	In vivo performance may vary with digestion	High
Taste-masked liquid	Improves adherence and caregiver administration	Release and palatability tradeoffs	Medium to high
Oral film	Convenient administration and dose flexibility	Drug loading and uniformity	Medium
Orodispersible tablet	Swallowing advantage	Low dose, bitter taste, absorption variability	Medium
Softgel with alternative lipid vehicle	Generic differentiation and allergen reduction	Limited clinical differentiation	Medium
Long-acting injectable	Reduces dosing frequency	Controlled-substance manufacturing and safety burden	Low to medium
Nasal or pulmonary delivery	Rapid onset and novel route	New clinical program and abuse potential	Selective

The strongest near-term opportunity is an improved oral formulation, not a new route of administration. A new route would require substantial clinical, toxicology, device, and abuse-liability investment.

How strong is the patent estate for dronabinol formulations?

The composition-of-matter position for dronabinol is commercially exhausted. Dronabinol was approved in the 1980s, so new exclusivity depends primarily on:

• Formulation claims.
• Concentration and excipient-ratio claims.
• Oral-solution claims.
• Taste-masking claims.
• Manufacturing-process claims.
• Device and dosing-system claims.
• Method-of-use claims.
• Abuse-deterrence claims.

Marinol's core product protection is no longer the primary barrier to generic entry. Syndros had a more recent formulation and product-specific development history, but its commercial protection must be analyzed through current FDA Orange Book listings, patent-family status, terminal disclaimers, PTA, PTE, and litigation records.

Patent claims are strongest when they combine:

1. A defined dronabinol concentration.
2. A narrow solvent or surfactant system.
3. A measurable stability or precipitation limitation.
4. A pharmacokinetic or food-effect limitation.
5. A manufacturing step that is difficult to design around.
6. A commercially necessary excipient ratio.

Broad claims covering "dronabinol plus a pharmaceutically acceptable excipient" are vulnerable to written-description, enablement, anticipation, and obviousness challenges. Narrow, experimentally supported claims are more defensible but may permit straightforward substitution of excipients.

What patents protect Syndros and other dronabinol products?

Syndros-related protection is more likely to center on oral-solution formulation architecture than on the dronabinol molecule itself. Public patent records include U.S. patents associated with dronabinol pharmaceutical compositions, including U.S. Patent No. 9,060,998. The relevant commercial question is not the existence of a patent family but whether an unexpired, Orange Book-listed claim reads on an ANDA product.

A diligence review should distinguish:

• Issued claims from abandoned applications.
• U.S. patents from foreign equivalents.
• Orange Book-listed patents from non-listed formulation patents.
• Claims covering the approved product from claims covering uncommercialized embodiments.
• Patent expiration from regulatory exclusivity expiration.
• Patent litigation from private settlement restrictions.

FDA's Orange Book identifies patents submitted for approved drug products and the associated expiration information. It does not establish infringement liability or guarantee that every formulation patent has been listed.[3]

When does dronabinol lose exclusivity?

Dronabinol has no remaining new-chemical-entity exclusivity based on the original Marinol approval. The commercial exclusivity landscape is product-specific.

Exclusivity or protection category	Marinol	Syndros	Generic capsules
Original NCE exclusivity	Expired	Not available for old active ingredient	Not applicable
Product-specific regulatory exclusivity	Expired	Historical approval-related exclusivity may have expired	Not applicable
Composition-of-matter patent	Expired or commercially exhausted	Not applicable to old molecule	Not applicable
Formulation patents	Historical and potentially product-specific	Potentially relevant	May be avoided or challenged
Method-of-use patents	Possible but limited by indication and claim scope	Possible	Relevant if listed
ANDA competition	Established	Depends on patent and regulatory barriers	Existing

Generic entrants can challenge listed patents through Paragraph IV certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed. The first ANDA applicant may qualify for 180-day exclusivity if statutory conditions are satisfied, but the value of that exclusivity depends on the applicable product and whether other first filers share or forfeit it.[4]

Which companies are challenging or competing with dronabinol?

Competition exists at several levels:

Generic capsule manufacturers

Generic sponsors compete directly with Marinol through standard capsule ANDAs. Their principal advantages are lower price and established manufacturing platforms. Their weaknesses are limited differentiation and reliance on the same basic sesame-oil softgel concept.

Oral-solution competitors

A competing oral solution would need to address one or more of the following:

• Lower ethanol content or no ethanol.
• Lower propylene glycol exposure.
• Better taste.
• More reliable dosing.
• Lower cost.
• Improved storage stability.
• Lower food-effect variability.
• More convenient packaging.

Cannabinoid substitutes

Dronabinol also competes with non-dronabinol cannabinoid products, including nabiximols outside the United States, cannabidiol-based products, and unapproved cannabis-derived products. These products are not direct generic substitutes because they differ in active ingredients, regulatory status, indications, cannabinoid ratios, and evidence base.

Drug-delivery and excipient suppliers

Commercial value may accrue to excipient and delivery-platform owners rather than to a new dronabinol sponsor. Relevant licensing targets include suppliers with:

• Self-emulsifying formulations.
• Taste-masking systems.
• Cyclodextrin technologies.
• Lipid nanoparticle or nanoemulsion platforms.
• Oral-film manufacturing.
• Controlled-substance packaging and dosing devices.

What manufacturing and intellectual-property barriers affect commercialization?

Manufacturing barriers are moderate for capsules and higher for differentiated liquids.

A capsule product requires control of:

• Dronabinol assay and content uniformity.
• Homogeneous dispersion in the oil vehicle.
• Oxidative stability.
• Softgel fill weight.
• Capsule-shell integrity.
• Light and oxygen exposure.
• Controlled-substance reconciliation.

An oral solution requires control of:

• Solubilization throughout shelf life.
• Precipitation after dilution.
• Dose uniformity across the bottle.
• Microbial quality.
• Container-closure compatibility.
• Ethanol and volatile-component loss.
• Syringe or dosing-device accuracy.
• Adsorption to packaging materials.

A formulation patent is more valuable when the manufacturing process is difficult to replicate at commercial scale. Process claims involving controlled mixing, temperature, order of addition, filtration, or packaging can create practical barriers even when the final excipient list is easy to identify.

What licensing deals could create value?

Potential licensing structures include:

1. An excipient-platform license to an established cannabinoid manufacturer.
2. A co-development agreement with a specialty pharmaceutical company.
3. A regional license for an alcohol-free oral solution.
4. A formulation license combined with contract manufacturing.
5. A device-and-formulation package for metered dosing.
6. A patent license for a food-effect-reducing lipid system.

The most defensible deal economics would link royalties to a measurable product advantage, such as reduced fed/fasted variability, improved stability, lower excipient burden, or superior dose accuracy. A license based only on a broad excipient combination is likely to face valuation pressure from design-around risk.

What is the revenue exposure from generic dronabinol entry?

Generic capsule entry puts price pressure on Marinol-like products. The remaining revenue opportunity is concentrated in:

• Oral solution products.
• Patients unable to swallow capsules.
• Institutional and caregiver-administered dosing.
• Products with differentiated tolerability.
• Specialty-pharmacy distribution.
• Geographic markets with limited cannabinoid competition.
• Formulations that support controlled, measurable titration.

Revenue protection depends less on the active ingredient and more on product-level differentiation. A sponsor should model three launch scenarios:

Scenario	Product profile	Expected market effect
Basic capsule generic	Same strengths and route	Rapid price erosion and share loss
Alternative capsule	Different oil or allergen profile	Moderate differentiation
Improved oral solution	Alcohol-free, taste-masked, stable	Higher margin and slower substitution
Advanced delivery system	Food-effect control or novel device	Potential premium, but higher clinical burden

What geographic opportunities exist for dronabinol excipients?

The United States offers the clearest pathway for product-specific formulation development through an NDA or 505(b)(2) strategy. Europe and other jurisdictions may offer opportunities where cannabinoid regulation, medical-cannabis access, and product availability differ.

Geographic diligence should cover:

• National cannabinoid scheduling.
• Whether dronabinol is approved as a medicine.
• Local reference-product requirements.
• Patent term and supplementary protection certificates.
• Excipient restrictions.
• Ethanol and propylene glycol limits.
• Medical-device registration for dosing systems.
• Import and controlled-substance permits.
• Local bioequivalence standards.

A formulation with an alcohol-free profile may have greater international utility than a product optimized only for the U.S. reference product.

Key Takeaways

• Dronabinol's core molecule is long off patent; formulation and product design carry the remaining strategic value.
• Marinol uses a sesame-oil softgel, while Syndros uses a solubilized oral solution.
• The strongest excipient opportunities are food-effect reduction, alcohol-free solubilization, taste masking, and dose-flexible liquid delivery.
• Generic capsule competition limits the value of undifferentiated softgel products.
• A formulation patent should rely on narrow, experimentally supported excipient ratios and performance limitations.
• Syndros-related patent and Orange Book analysis requires product-specific review of live listed patents and claim scope.
• A 505(b)(2) oral formulation could offer stronger commercial differentiation than a conventional ANDA capsule.
• Manufacturing controls, packaging compatibility, controlled-substance handling, and dosing-device accuracy are material IP and commercialization barriers.

FAQs

Can sesame oil be replaced in a generic dronabinol capsule?

Yes. A generic or reformulated capsule may use another lipid vehicle if it meets applicable quality, bioequivalence, stability, and regulatory requirements. Replacement creates a potential allergen and formulation-differentiation opportunity but does not automatically avoid every patent claim.

Is an alcohol-free dronabinol solution commercially feasible?

Yes, but the formulation must maintain solubility, dose uniformity, microbial quality, and shelf-life stability without ethanol. A successful alcohol-free product could target institutional procurement and patients who prefer to avoid ethanol-containing medicines.

Would a dronabinol oral film qualify as a generic product?

Usually not automatically. A materially different dosage form may require a 505(b)(2) application rather than a conventional ANDA, particularly if the formulation, absorption profile, labeling, or clinical performance differs from the reference product.

Can excipient patents block generic dronabinol capsules?

They can if an unexpired, enforceable claim covers the generic product and the patent is properly listed or otherwise enforceable. Practical risk depends on claim construction, design-around options, patent validity, and Paragraph IV litigation.

Which excipient property is most valuable for dronabinol?

The highest-value property is consistent systemic exposure with reduced food-effect variability. Taste, alcohol-free composition, dose flexibility, and improved stability are important commercial features, but pharmacokinetic consistency is more likely to support premium positioning and defensible patent claims.

References

1. U.S. Food and Drug Administration. (2023). Marinol (dronabinol) capsules prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (2023). Syndros (dronabinol) oral solution prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

5. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

6. U.S. Patent No. 9,060,998. (2015). Pharmaceutical compositions comprising dronabinol. U.S. Patent and Trademark Office.